Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. The Company leverages the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Aptevo’s ADAPTIR technology is suitable for producing immunotherapeutics for oncology, hematology, and autoimmune and inflammatory diseases.
Net income (Q2, 2019)
EBIT (Q2, 2019)
Market capitalization (16-Oct-2019)
Closing stock price (16-Oct-2019)
|USD||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q2, 2018||Q3, 2018||Q1, 2019||Q2, 2019|
|USD||Q2, 2016||Q1, 2017||Q2, 2017||Q3, 2017||Q1, 2018||Q2, 2018||Q3, 2018||Q1, 2019||Q2, 2019|
Depreciation and Amortization
When was Aptevo Therapeutics founded?
Aptevo Therapeutics was founded in 2016.
Who are Aptevo Therapeutics key executives?
Aptevo Therapeutics's key executives are Marvin L. White, Jeff Lamothe and Scott C. Stromatt.
How many employees does Aptevo Therapeutics have?
Aptevo Therapeutics has 118 employees.
What is Aptevo Therapeutics revenue?
Latest Aptevo Therapeutics annual revenue is $23.1 m.
What is Aptevo Therapeutics revenue per employee?
Latest Aptevo Therapeutics revenue per employee is $195.5 k.
Who are Aptevo Therapeutics competitors?
Competitors of Aptevo Therapeutics include XBiotech, Aeglea Biotherapeutics and Heat Biologics.
Where is Aptevo Therapeutics headquarters?
Aptevo Therapeutics headquarters is located at 2401 4th Ave #1050, Seattle.
Where are Aptevo Therapeutics offices?
Aptevo Therapeutics has an office in Seattle.
How many offices does Aptevo Therapeutics have?
Aptevo Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies